Bio-Rad Laboratories, Inc. logo

Bio-Rad Laboratories, Inc.

BIO

NYSEHealthcareMedical - Devices

Previous close

$380.03

+$3.57 · +0.95%

Aug 21, 4:00 PM ET

BIO company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

64

Undervalued

Momentum

42

Neutral

Sentiment

66

Bullish

Risk resilience

64

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Norman D. Schwartz
Listed since
Feb 27, 1980
Employees
7,450

Market position

Day range

Current $380.03

52-week range

Current $380.03

Open
$385.8
Previous close
$376.46
Volume
302.71K
0.85× average
Average volume
354.9K
Average daily volume
Market cap
10.23B USD
Beta
1.05
Market reference 1
50-day average
$315.93
+20.29% above average
200-day average
$298.24
+27.43% above average

Earnings

Latest fiscal-year EPS
27.87
FY2025
Latest fiscal-year revenue
2.58B USD
FY2025 · +0.65% year over year
Next fiscal-year EPS consensus
9.64
FY2026 · 2 analysts
Next fiscal-year revenue consensus
2.58B USD
FY2026 · 3 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend167.0962.04-43-148.05FY21FY22FY23FY24FY25FY26FY27

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend2.96B2.8B2.65B2.49BFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$350

7.90% downside
Past 12 months12-month forecastHigh $390Average $350Low $310

Rating distribution

14 ratings
Strong buy17%
Buy750%
Hold643%
Sell00%
Strong sell00%

BIO peers

ETFs holding BIO

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BIO

research.disclaimer